Pimavanserin
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Agitation and Aggression in Alzheimer's Disease
Conditions
Agitation and Aggression in Alzheimer's Disease
Trial Timeline
Feb 23, 2017 → Feb 25, 2019
NCT ID
NCT03118947About Pimavanserin
Pimavanserin is a phase 2 stage product being developed by Acadia Pharmaceuticals for Agitation and Aggression in Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03118947. Target conditions include Agitation and Aggression in Alzheimer's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05796167 | Phase 1 | Withdrawn |
| NCT05357612 | Approved | Recruiting |
| NCT04809116 | Approved | Withdrawn |
| NCT05555615 | Phase 2/3 | Terminated |
| NCT04292223 | Approved | Completed |
| NCT04000009 | Phase 3 | Terminated |
| NCT03623321 | Phase 3 | Completed |
| NCT03482882 | Phase 2 | Completed |
| NCT03118947 | Phase 2 | Completed |
| NCT03121586 | Phase 3 | Terminated |
| NCT03018340 | Phase 2 | Completed |
Competing Products
20 competing products in Agitation and Aggression in Alzheimer's Disease